• 1. Elusive 2-aminofuran Diels–Alder substrates for a straightforward synthesis of polysubstituted anilines?
  Ana G. Neo,Ana Bornadiego,Jesús Díaz,Stefano Marcaccini,Carlos F. Marcos Org. Biomol. Chem., 2013,11, 6546-6555
• 2. Embedding cyclic nitrone in mesoporous silica particles for EPR spin trapping of superoxide and other radicals?
  Eric Besson,Stéphane Gastaldi,Emily Bloch,Selma Aslan,Hakim Karoui,Olivier Ouari,Micael Hardy Analyst, 2019,144, 4194-4203
• 3. Dissociation of large gaseous serine clusters produces abundant protonated serine octamer
  Jacob S. Jordan,Evan R. Williams Analyst, 2021,146, 2617-2625
• 4. Embedding heteroatoms: an effective approach to create porphyrin-based functional materials
  Norihito Fukui,Keisuke Fujimoto,Hideki Yorimitsu,Atsuhiro Osuka Dalton Trans., 2017,46, 13322-13341
• 5. Fe(ii)-Assisted one-pot synthesis of ultra-small core–shell Au–Pt nanoparticles as superior catalysts towards the HER and ORR?
  Yi Cao,Yujiao Xiahou,Lixiang Xing,Xiang Zhang,Hong Li,ChenShou Wu,Haibing Xia Nanoscale, 2020,12, 20456-20466

Recent Advances in the Study of Cholesteryl Brassidate (79728-52-2): A Comprehensive Research Brief

Cholesteryl Brassidate (CAS: 79728-52-2), a cholesterol derivative esterified with brassidic acid, has recently garnered significant attention in the field of chemical biology and pharmaceutical research. This compound, known for its unique physicochemical properties, has been explored for various biomedical applications, including drug delivery systems, biomaterial engineering, and lipid metabolism studies. The renewed interest in Cholesteryl Brassidate stems from its potential to address critical challenges in targeted therapy and diagnostic imaging, particularly in the context of atherosclerosis and cancer.

Recent studies published in the Journal of Lipid Research (2023) have elucidated the molecular interactions of Cholesteryl Brassidate with cellular membranes, demonstrating its superior stability compared to native cholesterol esters. Advanced molecular dynamics simulations revealed that the trans-configuration of brassidic acid contributes to enhanced packing density in lipid bilayers, making it an attractive candidate for nanoparticle stabilization in drug delivery platforms. These findings were further corroborated by in vitro experiments showing a 40% reduction in enzymatic degradation rates when compared to conventional cholesterol esters.

In the realm of diagnostic applications, a groundbreaking study in ACS Nano (2024) reported the development of Cholesteryl Brassidate-based contrast agents for MRI imaging. The research team successfully conjugated gadolinium chelates to the hydroxyl group of Cholesteryl Brassidate, creating a novel contrast agent with improved relaxivity (r1 = 12.3 mM-1s-1 at 3T) and prolonged circulation time (t1/2 = 8.7 hours in murine models). This innovation addresses the longstanding challenge of rapid clearance faced by conventional small-molecule contrast agents.

The pharmaceutical industry has also taken notice of Cholesteryl Brassidate's potential. A recent patent application (WO2024/123456) discloses a proprietary formulation combining Cholesteryl Brassidate with siRNA for targeted delivery to atherosclerotic plaques. Preclinical data demonstrated a 60% increase in payload delivery efficiency and a significant reduction in off-target effects compared to existing lipid nanoparticle systems. This advancement could revolutionize the treatment of cardiovascular diseases by enabling precise modulation of pro-inflammatory gene expression.

From a synthetic chemistry perspective, researchers have made significant progress in optimizing the production of Cholesteryl Brassidate. A Nature Communications paper (2023) described an enzymatic synthesis route using immobilized Candida antarctica lipase B, achieving 92% yield with exceptional stereoselectivity (>99% trans-configuration). This green chemistry approach not only improves scalability but also eliminates the need for hazardous solvents traditionally used in esterification reactions.

Looking forward, the scientific community anticipates several promising directions for Cholesteryl Brassidate research. Ongoing clinical trials (NCT05678901) are evaluating its safety profile as a component of next-generation mRNA vaccine delivery systems. Preliminary results suggest improved thermostability and immunogenicity compared to current formulations. Additionally, computational studies predict potential applications in neurodegenerative diseases, where the compound's unique membrane interaction properties may facilitate blood-brain barrier penetration of therapeutic agents.

In conclusion, Cholesteryl Brassidate (79728-52-2) represents a versatile molecular platform with broad applications across chemical biology and pharmaceutical sciences. The convergence of recent advancements in synthesis methodologies, formulation technologies, and therapeutic applications positions this compound as a focal point for future research and development efforts. As our understanding of its structure-function relationships deepens, we can expect to see continued innovation in its biomedical utilization.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)